决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:Direct visualization of chimeric antigen receptors on primary human T cells using dSTORM super-resolution microscopy.
嵌合抗原受体(CAR)T 细胞是血液系统恶性肿瘤的变革性治疗手段,该领域正共同努力将这一成功转化应用于实体瘤和自身免疫性疾病。
CAR-T 是治疗血液系统恶性肿瘤的变革性疗法,该领域正协同努力将这一成功拓展至实体瘤和自身免疫性疾病。研究者希望准确评估 CAR 的组织结构和时空表达,以阐明 CAR-T 介导抗肿瘤活性的机制细节,并评估 CAR-T 产品的效力和安全性。本研究使用靶向 IgG4 的 F(ab)₂ 直接标记 CAR,再采用直接随机光学重建显微镜(dSTORM)进行超分辨成像。该方法可在单分子分辨率下检测人原代 T 细胞表面 CAR 表达,且不受 CAR 特异性影响。研究者将这一直接 CAR 检测方法与 CAR-T 表型评估结合,展示其用于获得详细机制认识的潜在应用。利用该新方法,可在背景信号极低的情况下检测靶向 SLAMF7、BCMA 和 CD19 的 CAR 表面表达。研究确定 T 细胞亚型、供者材料和 CAR 构建体是影响 CAR 表面表达的因素,并发现 CAR 表面表达可能影响 CAR-T 活化状态。本文提供了一种无需标签、用于了解 CAR 表面表达的新方法,展示了超分辨显微镜在指导合成免疫受体应用于 CAR-T 治疗方面的潜力,并可能为开展更精细的组合研究奠定基础,进一步提高 CAR-T 免疫治疗疗效、预测治疗结局并确保患者获得最佳照护。
Chimeric antigen receptor (CAR) T cells are a transformative treatment for hematological malignancies, and concerted efforts in the field are aiming to translate this success to solid tumors and autoimmune diseases. There is a desire in the field to accurately assess CAR organization and spatiotemporal expression to elucidate mechanistic details of CAR-T cell mediated anti-tumor activity and enable evaluation of the potency and safety of CAR-T cell products. We applied an IgG4-targeted F(ab) 2 to achieve direct CAR labeling for super-resolution microscopy by direct stochastic optical reconstruction microscopy ( d STORM). This enabled us to determine CAR surface expression on human primary T cells with single-molecule resolution independent of CAR specificity. We combined this direct CAR detection approach with a phenotypic assessment of the CAR-T cells, highlighting prospective applications to gain detailed mechanistic insights. With this new approach, we were able to detect the surface expression of CARs targeting SLAMF7, BCMA and CD19 with minimal background. We determined T cell subtype, donor material, and CAR construct as contributing factors shaping CAR surface expression and identified putative influence of CAR surface expression on CAR-T cell activation state. Here we provide a novel, tag-free approach to gain insights into the surface expression of CARs, illustrating the potential of super-resolution microscopy to inform the application of synthetic immune receptors for CAR-T cell therapy, potentially building the basis for more intricate and combinatorial studies to further improve the efficacy of CAR-T cell immunotherapy, predict therapeutic outcome and ensure optimal care for patients.
MEMBER ACCOUNT
登录成功会直接打开下一页。